<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement. RemeGen Co., Ltd. has issued preliminary 2025 financial estimates indicating a sharp rebound in performance, with operating revenue expected to reach about RMB3.25 billion, up roughly 89% year on year, and net profit attributable to shareholders projected at around RMB716 million, compared with a substantial loss in 2024. The turnaround is driven by rapid sales growth of its core biologic drugs telitacicept and disitamab vedotin in China, a major global licensing deal granting Vor Biopharma exclusive rights to develop and commercialize telitacicept outside Greater China that boosts technology licensing income and shifts some overseas R&amp;D costs to the partner, as well as internal cost and efficiency measures that have lowered production costs, improved gross margins and reduced sales expenses; even after excluding non-recurring gains, notably from fair-value changes of warrants tied to the licensing transaction, the company expects to move from loss to profit in 2025, signaling a significant improvement in its profitability profile and market positioning. The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page. More about RemeGen Co. Ltd. Class H RemeGen Co., Ltd. is a biopharmaceutical company based in China focused on developing and commercializing innovative biologic therapies. Its core marketed products include telitacicept and disitamab vedotin, with a growing emphasis on both domestic sales in the PRC and global partnering, particularly through out-licensing arrangements for its pipeline assets. Average Trading Volume: 4,652,921 Technical Sentiment Signal: Buy Current Market Cap: HK$58.65B For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.</div>

560600

159506

159615

RemeGen Co. Ltd. forecasts a profit turnaround in 2025, projecting operating revenue of approximately RMB3.25 billion, an 89% increase year-on-year, and a net profit of around RMB716 million. This improvement is attributed to strong sales of its biologic drugs, a global licensing deal with Vor Biopharma, and internal cost efficiencies. The company expects to shift from a loss in 2024 to profitability in 2025, enhancing its market position. The current analyst rating for RemeGen stock (HK:9995) is a Hold with a price target of HK$88.00.

Tip Ranks

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

REMEGEN

E Fund CSI 300 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Research Sector 100 ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal